340 related articles for article (PubMed ID: 29396713)
21. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Mesa R; Vannucchi AM; Yacoub A; Zachee P; Garg M; Lyons R; Koschmieder S; Rinaldi C; Byrne J; Hasan Y; Passamonti F; Verstovsek S; Hunter D; Jones MM; Zhen H; Habr D; Martino B
Br J Haematol; 2017 Jan; 176(1):76-85. PubMed ID: 27858987
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
23. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Mesa R; Verstovsek S; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Zhen H; Jones MM; Parasuraman S; Li J; Côté I; Habr D; Vannucchi AM
Eur J Haematol; 2016 Aug; 97(2):192-200. PubMed ID: 26608702
[TBL] [Abstract][Full Text] [Related]
24. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
25. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
[TBL] [Abstract][Full Text] [Related]
26. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
27. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib: A Review in Polycythaemia Vera.
McKeage K
Drugs; 2015 Oct; 75(15):1773-81. PubMed ID: 26362333
[TBL] [Abstract][Full Text] [Related]
29. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Vaddi K; Verstovsek S; Kiladjian JJ
Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
[TBL] [Abstract][Full Text] [Related]
32. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
Verstovsek S; Harrison CN; Kiladjian JJ; Miller C; Naim AB; Paranagama DC; Habr D; Vannucchi AM
Leuk Res; 2017 May; 56():52-59. PubMed ID: 28193568
[TBL] [Abstract][Full Text] [Related]
33. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
Harrison CN; Griesshammer M; Miller C; Masszi T; Passamonti F; Zachee P; Durrant S; Pane F; Guglielmelli P; Verstovsek S; Jones MM; Hunter DS; Sun W; Li J; Khan M; Habr D; Kiladjian JJ
Br J Haematol; 2018 Jul; 182(2):279-284. PubMed ID: 29984424
[No Abstract] [Full Text] [Related]
35. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Kremyanskaya M; Mascarenhas J; Hoffman R
Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
[TBL] [Abstract][Full Text] [Related]
36. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
37. Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.
Kirito K; Sakamoto M; Enomoto N
Intern Med; 2016; 55(10):1341-4. PubMed ID: 27181544
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
39. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
40. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
